Aerie Pharmaceuticals Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Aerie Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AERI, but not buy additional shares or sell existing shares.
View analyst ratings for Aerie Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Aerie Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aerie Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Aerie Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Aerie Pharmaceuticals.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) released its earnings results on Tuesday, August, 3rd. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.65) by $0.02. Aerie Pharmaceuticals had a negative net margin of 175.35% and a negative trailing twelve-month return on equity of 1,531.00%.
View Aerie Pharmaceuticals' earnings history.

Aerie Pharmaceuticals' stock was trading at $14.55 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AERI shares have decreased by 18.1% and is now trading at $11.92.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued 12-month target prices for Aerie Pharmaceuticals' stock. Their forecasts range from $9.00 to $29.00. On average, they anticipate Aerie Pharmaceuticals' share price to reach $21.13 in the next twelve months. This suggests a possible upside of 77.3% from the stock's current price.
View analysts' price targets for Aerie Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Aerie Pharmaceuticals include Alector (ALEC), REGENXBIO (RGNX), Rubius Therapeutics (RUBY), Valneva (VALN), Immunocore (IMCR), Replimune Group (REPL), Ocugen (OCGN), AlloVir (ALVR), Atara Biotherapeutics (ATRA), Agenus (AGEN), Sangamo Therapeutics (SGMO), Inhibrx (INBX), Vaxcyte (PCVX), Coherus BioSciences (CHRS) and Krystal Biotech (KRYS).
View all of AERI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include (CGC), Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Puma Biotechnology (PBYI), NVIDIA (NVDA), Wells Fargo & Company (WFC) and Alibaba Group (BABA).

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

Aerie Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.21%), Bank of America Corp DE (5.56%), William Blair Investment Management LLC (4.63%), Levin Capital Strategies L.P. (2.86%), Citigroup Inc. (2.65%) and Rice Hall James & Associates LLC (2.65%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski and Gerald D Cagle.
View institutional ownership trends for Aerie Pharmaceuticals.

AERI stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Woodline Partners LP, Rice Hall James & Associates LLC, Tri Locum Partners LP, Principal Financial Group Inc., Atika Capital Management LLC, Granite Investment Partners LLC, and Bank of America Corp DE.
View insider buying and selling activity for Aerie Pharmaceuticals or view top insider-selling stocks.

AERI stock was purchased by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Integral Health Asset Management LLC, Levin Capital Strategies L.P., M&G Investment Management Ltd., State Street Corp, Renaissance Technologies LLC, Millennium Management LLC, and Vanguard Group Inc..
View insider buying and selling activity for Aerie Pharmaceuticals or or view top insider-buying stocks.

Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AERI stock can currently be purchased for approximately $11.92.

Aerie Pharmaceuticals has a market capitalization of $563.03 million and generates $83.14 million in revenue each year. The company earns $-183,100,000.00 in net income (profit) each year or ($3.12) on an earnings per share basis.

Aerie Pharmaceuticals employs 365 workers across the globe.

The official website for Aerie Pharmaceuticals is www.aeriepharma.com.

Aerie Pharmaceuticals is headquartered at 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703.

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at (919) 237-5300 or via email at [email protected].